The remarkable journey of Scott Rocklage begins at the University of California, Berkeley, where he he earned a bachelor of science degree in chemistry. He went on to earn a doctorate degree at one of the world’s most prestigious educational and research institutions, the Massachusetts Institute of Technology (MIT).
While at MIT he worked under world renowned and Nobel Prize winning chemist Dr. Richard Schrock. Rocklage’s stellar educational achievements made him well-prepared to enter the field of healthcare management, especially where that field dovetails with the development of pharmaceuticals.
In fact, Dr. Rocklage would go on to lead efforts that resulted in approval of three new drugs applications with the FDA — Omniscan, Teslascan and Cubicin.
Dr. Rocklage’s natural leadership abilities served him well in his roles as Chairman and CEO of Cubist Pharmaceuticals. He also served as president and CEO of Nycomed Salutar. Prior to that, he worked in R&D at Salutar and Catalytica.
Boardroom experience is also a significant part of his résumé. Dr. Rocklage is a former board chairman of Relypsa and Novira. Today he serves as board chair of Rennovia, Kinestral and Cidara. Additionally, he has a seat on the boards of Epirus and Pulmatrix.
Dr. Rocklage’s experience in the lab developing new drugs is considerable. He has invented or co-invented 30 new patents. His publication history shows that he has written or contributed to more than 100 peer-reviewed papers.
Today Dr. Rocklage is a Managing Partner of 5AM Ventures.
5AM Ventures is a venture capital firm that builds next-generation life science companies. It has developed a significant reputation for delivering spectacular returns for investors. The company supports other companies that strive to solve vital healthcare needs with cutting-edge medical research and applied science.
Dr. Rocklage’s educational background and deep experience garnered from a long, successful career has proven a perfect fit with the mission of 5AM. He brings a potent mixture of scientific, medical, operational, legal and financial expertise to a company that is driven to remain on the cutting edge of medical research development.
Learn more about Scott Rocklage: